TNFSF15 gene
Boehringer Ingelheim Signs $1.3 Billion Deal for Simcere’s Preclinical IBD Bispecific SIM0709
Boehringer Ingelheim; Simcere; SIM0709; IBD; bispecific antibody; TL1A; IL-23p19; licensing deal
Sanofi and Teva Pioneer Next-Generation IBD Treatment with Promising TL1A Antibody Results
Inflammatory Bowel Disease (IBD), TL1A Antibody, Duvakitug, Crohn’s Disease, Ulcerative Colitis, Precision Medicine, Immunology, Gastrointestinal Diseases